严重的血小板缺血症使奥比努祖马布的初始治疗复杂化:它比我们想象的更常见吗?
Umut Yılmaz1, Selin Küçükyurt1, Muhlis Cem Ar1
1Division of Hematology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Fatih, Istanbul, Turkey.
Oncology and therapy
|January 22, 2024
概括
奥本图祖马布诱导的急性血小板缺血 (OIAT) 可能在第一次输液后发生早期和严重. 这种独特的,可能不会复发的事件需要进一步的临床关注和调查.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 血小板缺血是obinutuzumab的一种已知的副作用.
- 病例报告强调了一个独特的,早期发作的严重血小板缺血与obinutuzumab.
- 与rituximab的比较显示,血小板缺血的频率各不相同.
研究的目的:
- 为了调查由奥比努图祖马布诱导的急性血小板缩症 (OIAT).
- 描述OIAT的特征,时间和临床过程.
- 评估OIAT再次出现的可能性.
主要方法:
- 从单一诊所回顾患者记录的回顾性审查.
- 在临床试验之外接受奥比努祖马布的患者中识别OIAT病例.
- 三个已确认的OIAT病例的详细描述.
主要成果:
- 在24名患者中发现了三例严重的OIAT病例.
- 这三名患者在第一个奥比努图祖马布输注后的5天内都发生了OIAT.
- 患者对输血反应良好,在几天内恢复,没有严重出血;第二次循环没有复发.
结论:
- 奥本图祖马布诱导的急性血小板缺血 (OIAT) 是一个独特的临床事件.
- OIAT似乎很频繁,可能不会复发,并且在初次暴露后很快发生.
- OIAT需要更多的临床认可和进一步研究.
关键词:
不良事件是不良事件.抗CD20单克隆抗体的抗体.这就是Obinutuzumab.奥比努图祖马布诱导的急性血小板缺血症.血小板减少症 (Thrombocytopenia) 是一个严重的疾病.有毒性 有毒性更多相关视频
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
1.4K
06:07Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
Published on: February 5, 2020
5.7K
相关概念视频
Blood Transfusion and Agglutination
10.8K
Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
10.8K
Disorders of Hemostasis
918
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
918
Anticoagulant Drugs: Low-Molecular-Weight Heparins
701
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
701
